Luiz A Basso

List of Publications by Year in Descending Order

187 papers	3,641 citations	34 h-index	48 g-index
196 ext. papers	3,983 ext. citations	4.1 avg, IF	4.77 L-index

#	Paper	IF	Citations
187	Rethinking the MtInhA tertiary and quaternary structure flexibility: a molecular dynamics view.. *Journal of Molecular Modeling*, **2022**, 28, 140	2	0
186	Synthesis and Antimycobacterial Activity of 3-Phenyl-1H-indoles. *Molecules*, **2021**, 26, 5148	4.8	
185	Effects of tafenoquine against active, dormant and resistant Mycobacterium tuberculosis. *Tuberculosis*, **2021**, 128, 102089	2.6	1
184	Therapeutic effect of uridine phosphorylase 1 (UPP1) inhibitor on liver fibrosis in vitro and in vivo. *European Journal of Pharmacology*, **2021**, 890, 173670	5.3	2
183	Anti-tubercular profile of new selenium-menadione conjugates against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain and multidrug-resistant clinical isolates. *European Journal of Medicinal Chemistry*, **2021**, 209, 112859	6.8	5
182	8-Mercaptoguanine-based inhibitors of dihydroneopterin aldolase: synthesis, inhibition and docking studies. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2021**, 36, 847-855	5.6	
181	Ultrasound-Assisted Synthesis of 4-Alkoxy-2-methylquinolines: An Efficient Method toward Antitubercular Drug Candidates. *Molecules*, **2021**, 26,	4.8	3
180	Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts. *Biomedicine and Pharmacotherapy*, **2021**, 139, 111672	7.5	1
179	EPSP Synthase-Depleted Cells Are Aromatic Amino Acid Auxotrophs in Mycobacterium smegmatis.. *Microbiology Spectrum*, **2021**, 9, e0000921	8.9	0
178	CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence. *Investigational New Drugs*, **2020**, 38, 1653-1663	4.3	1
177	Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs. *Molecules*, **2020**, 25,	4.8	20
176	Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents. *European Journal of Medicinal Chemistry*, **2020**, 192, 112179	6.8	13
175	Light-induced disruption of an acyl hydrazone link as a novel strategy for drug release and activation: isoniazid as a proof-of-concept case. *Inorganic Chemistry Frontiers*, **2020**, 7, 859-870	6.8	8
174	Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy. *Regulatory Toxicology and Pharmacology*, **2020**, 111, 104553	3.4	4
173	Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. *Frontiers in Chemistry*, **2020**, 8, 586294	5	9
172	Resistance Reversed in KatG Mutants of Mycobacterium tuberculosis. *Trends in Microbiology*, **2019**, 27, 655-656	12.4	2
171	Synthesis and photophysical, thermal and antimycobacterial properties of novel 6-amino-2-alkyl(aryl/heteroaryl)-4-(trifluoromethyl) quinolines. *New Journal of Chemistry*, **2019**, 43, 12375-12384	3.6	8

170	Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer. *Journal of Medicinal Chemistry*, **2019**, 62, 1231-1245	8.3	7
169	Assessing the role of deoD gene in Mycobacterium tuberculosis in vitro growth and macrophage infection. *Microbial Pathogenesis*, **2018**, 119, 60-64	3.8	1
168	Effect of the bradykinin 1 receptor antagonist SSR240612 after oral administration in Mycobacterium tuberculosis-infected mice. *Tuberculosis*, **2018**, 109, 1-7	2.6	2
167	Preclinical pharmacokinetic profiling of IQG-607, a potential oral metallodrug to treat tuberculosis. *European Journal of Pharmaceutical Sciences*, **2018**, 111, 393-398	5.1	4
166	Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing. *International Journal of Antimicrobial Agents*, **2018**, 51, 378-384	14.3	13
165	Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in ?. *Frontiers in Microbiology*, **2018**, 9, 880	5.7	9
164	Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis. *PLoS ONE*, **2018**, 13, e0202568	3.7	10
163	Revisiting Activation of and Mechanism of Resistance to Compound IQG-607 in Mycobacterium tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	8
162	Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy. *Journal of Inorganic Biochemistry*, **2018**, 179, 71-81	4.2	13
161	1H-Benzo[d]imidazoles and 3,4-dihydroquinazolin-4-ones: Design, synthesis and antitubercular activity. *European Journal of Medicinal Chemistry*, **2018**, 155, 153-164	6.8	15
160	Preclinical safety evaluation of IQG-607 in rats: Acute and repeated dose toxicity studies. *Regulatory Toxicology and Pharmacology*, **2017**, 86, 11-17	3.4	11
159	Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme. *Scientific Reports*, **2017**, 7, 46696	4.9	4
158	Thermodynamics, functional and structural characterization of inosine□uridine nucleoside hydrolase from Leishmania braziliensis. *RSC Advances*, **2017**, 7, 48861-48875	3.7	1
157	Characterisation of iunH gene knockout strain from Mycobacterium tuberculosis. *Memorias Do Instituto Oswaldo Cruz*, **2017**, 112, 203-208	2.6	5
156	Toxicological profile of IQG-607 after single and repeated oral administration in minipigs: An essential step towards phase I clinical trial. *Regulatory Toxicology and Pharmacology*, **2017**, 90, 78-86	3.4	9
155	Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only. *Scientific Reports*, **2017**, 7, 6826	4.9	8
154	Biochemical, thermodynamic and structural studies of recombinant homotetrameric adenylosuccinate lyase from Leishmania braziliensis. *RSC Advances*, **2017**, 7, 54347-54360	3.7	3
153	New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2017**, 126, 491-501	6.8	28

152	Construction of Mycobacterium tuberculosis cdd knockout and evaluation of invasion and growth in macrophages. *Memorias Do Instituto Oswaldo Cruz*, **2017**, 112, 785-789	2.6	1
151	Inhibitory activity of pentacyano(isoniazid)ferrate(II), IQG-607, against promastigotes and amastigotes forms of Leishmania braziliensis. *PLoS ONE*, **2017**, 12, e0190294	3.7	7
150	Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection. *International Journal of Antimicrobial Agents*, **2016**, 48, 203-7	14.3	19
149	2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains. *ACS Medicinal Chemistry Letters*, **2016**, 7, 235-9	4.3	27
148	Mycobacterium tuberculosis histidinol dehydrogenase: biochemical characterization and inhibition studies. *RSC Advances*, **2016**, 6, 28406-28418	3.7	2
147	Mode of action of recombinant hypoxanthine□guanine phosphoribosyltransferase from Mycobacterium tuberculosis. *RSC Advances*, **2015**, 5, 74671-74683	3.7	4
146	Gene replacement and quantitative mass spectrometry approaches validate guanosine monophosphate synthetase as essential for growth. *Biochemistry and Biophysics Reports*, **2015**, 4, 277-282	2.2	4
145	Functional and structural evidence for the catalytic role played by glutamate-47 residue in the mode of action of Mycobacterium tuberculosis cytidine deaminase. *RSC Advances*, **2015**, 5, 830-840	3.7	2
144	Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies. *European Journal of Medicinal Chemistry*, **2015**, 90, 436-47	6.8	13
143	A greener approach toward gadolinium-based contrast agents. *RSC Advances*, **2014**, 4, 9880-9884	3.7	3
142	The kinetic mechanism of Human Thymidine Phosphorylase - a molecular target for cancer drug development. *Molecular BioSystems*, **2014**, 10, 592-604		9
141	[Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy. *Journal of Inorganic Biochemistry*, **2014**, 140, 236-44	4.2	26
140	Biochemical characterization of Mycobacterium tuberculosis IMP dehydrogenase: kinetic mechanism, metal activation and evidence of a cooperative system. *RSC Advances*, **2014**, 4, 26271-26287	3.7	1
139	Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicin via SIRT1 modulation. *Journal of Natural Products*, **2014**, 77, 2190-5	4.9	31
138	Production of recombinant human annexin V by fed-batch cultivation. *BMC Biotechnology*, **2014**, 14, 33	3.5	6
137	Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. *Investigational New Drugs*, **2014**, 32, 1301-7	4.3	9
136	IQG-607 abrogates the synthesis of mycolic acids and displays intracellular activity against Mycobacterium tuberculosis in infected macrophages. *International Journal of Antimicrobial Agents*, **2014**, 43, 82-5	14.3	21
135	Real time PCR quantification of viable Mycobacterium tuberculosis from sputum samples treated with propidium monoazide. *Tuberculosis*, **2014**, 94, 421-7	2.6	11

134	Cloning and characterization of bifunctional enzyme farnesyl diphosphate/geranylgeranyl diphosphate synthase from Plasmodium falciparum. *Malaria Journal*, **2013**, 12, 184	3.6	22
133	Biochemical characterization of recombinant nucleoside hydrolase from Mycobacterium tuberculosis H37Rv. *Archives of Biochemistry and Biophysics*, **2013**, 538, 80-94	4.1	6
132	Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. *Journal of Chemical Information and Modeling*, **2013**, 53, 2390-401	6.1	58
131	Ultrasound-assisted improvement of drug solubility: a simple and useful method for the formation of salts from 4-hydroxy-6-methyl-3-nitropyridin-2(1H)-one. *Monatshefte F□ Chemie*, **2013**, 144, 1165-1170	1.4	
130	Targeting the histidine pathway in Mycobacterium tuberculosis. *Current Topics in Medicinal Chemistry*, **2013**, 13, 2866-84	3	21
129	Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. *Journal of Medicinal Chemistry* , **2013**, 56, 8892-902	8.3	14
128	Kinetic mechanism and energetics of binding of phosphoryl group acceptors to Mycobacterium tuberculosis cytidine monophosphate kinase. *Archives of Biochemistry and Biophysics*, **2013**, 536, 53-63	4.1	1
127	The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models. *Bone*, **2013**, 52, 167-75	4.7	3
126	Recombinant Erwinia carotovora l-asparaginase II production in Escherichia coli fed-batch cultures. *Brazilian Journal of Chemical Engineering*, **2013**, 30, 245-256	1.7	14
125	The mode of action of recombinant Mycobacterium tuberculosis shikimate kinase: kinetics and thermodynamics analyses. *PLoS ONE*, **2013**, 8, e61918	3.7	13
124	Biochemical characterization of uracil phosphoribosyltransferase from Mycobacterium tuberculosis. *PLoS ONE*, **2013**, 8, e56445	3.7	14
123	Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design. *Journal of Biological Inorganic Chemistry*, **2012**, 17, 275-83	3.7	32
122	Combining molecular dynamics and docking simulations of the cytidine deaminase from Mycobacterium tuberculosis H37Rv. *Journal of Molecular Modeling*, **2012**, 18, 467-79	2	7
121	Pyrimidin-2(1H)-ones based inhibitors of Mycobacterium tuberculosis orotate phosphoribosyltransferase. *European Journal of Medicinal Chemistry*, **2012**, 54, 113-22	6.8	16
120	Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection. *International Journal of Antimicrobial Agents*, **2012**, 40, 182-5	14.3	27
119	Biochemical characterization of recombinant guaA-encoded guanosine monophosphate synthetase (EC 6.3.5.2) from Mycobacterium tuberculosis H37Rv strain. *Archives of Biochemistry and Biophysics*, **2012**, 517, 1-11	4.1	10
118	Crystal structure and molecular dynamics studies of purine nucleoside phosphorylase from Mycobacterium tuberculosis associated with acyclovir. *Biochimie*, **2012**, 94, 155-65	4.6	15
117	Role of Serine140 in the mode of action of Mycobacterium tuberculosis □ketoacyl-ACP Reductase (MabA). *BMC Research Notes*, **2012**, 5, 526	2.3	7

116	Wild-type phosphoribosylpyrophosphate synthase (PRS) from Mycobacterium tuberculosis: a bacterial class II PRS?. *PLoS ONE*, **2012**, 7, e39245	3.7	11
115	Molecular, kinetic and thermodynamic characterization of Mycobacterium tuberculosis orotate phosphoribosyltransferase. *Molecular BioSystems*, **2012**, 8, 572-86		16
114	Capillary bioreactors based on human purine nucleoside phosphorylase: a new approach for ligands identification and characterization. *Journal of Chromatography A*, **2012**, 1232, 110-5	4.5	20
113	UMP kinase from Mycobacterium tuberculosis: Mode of action and allosteric interactions, and their likely role in pyrimidine metabolism regulation. *Archives of Biochemistry and Biophysics*, **2011**, 505, 202-12	4.1	11
112	Crystal structure determination and dynamic studies of Mycobacterium tuberculosis Cytidine deaminase in complex with products. *Archives of Biochemistry and Biophysics*, **2011**, 509, 108-15	4.1	6
111	Molecular, kinetic, thermodynamic, and structural analyses of Mycobacterium tuberculosis hisD-encoded metal-dependent dimeric histidinol dehydrogenase (EC 1.1.1.23). *Archives of Biochemistry and Biophysics*, **2011**, 512, 143-53	4.1	9
110	Pyrimidine salvage pathway in Mycobacterium tuberculosis. *Current Medicinal Chemistry*, **2011**, 18, 1286-98	4.3	42
109	Recombinant Escherichia coli GMP reductase: kinetic, catalytic and chemical mechanisms, and thermodynamics of enzyme-ligand binary complex formation. *Molecular BioSystems*, **2011**, 7, 1289-305		16
108	Analysis of select members of the E26 (ETS) transcription factors family in colorectal cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2011**, 458, 421-30	5.1	15
107	Molecular cloning and transgenic expression of a synthetic human erythropoietin gene in tobacco. *Applied Biochemistry and Biotechnology*, **2011**, 165, 652-65	3.2	4
106	Kinetic mechanism determination and analysis of metal requirement of dehydroquinate synthase from Mycobacterium tuberculosis H37Rv: an essential step in the function-based rational design of anti-TB drugs. *Molecular BioSystems*, **2011**, 7, 119-28		10
105	Hydrogen/deuterium exchange mass spectrometry for characterizing phosphoenolpyruvate-induced structural transitions in Mycobacterium tuberculosis 5-enolpyruvylshikimate-3-phosphate synthase (EC 2.5.1.1). *International Journal of Mass Spectrometry*, **2011**, 302, 12-18	1.9	2
104	Shikimate kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: kinetics and structural dynamics of a potential molecular target for drug development. *Current Medicinal Chemistry*, **2011**, 18, 1299-310	4.3	4
103	Enzyme Mechanism and Slow-Onset Inhibition of Plasmodium falciparum Enoyl-Acyl Carrier Protein Reductase by an Inorganic Complex. *Enzyme Research*, **2011**, 2011, 642758	2.4	2
102	Purine Salvage Pathway in Mycobacterium tuberculosis. *Current Medicinal Chemistry*, **2011**, 18, 1258-75	4.3	44
101	Purine nucleoside phosphorylase activity and expression are upregulated in sites affected by periodontal disease. *Journal of Periodontal Research*, **2010**, 45, 664-71	4.3	7
100	An inorganic complex that inhibits Mycobacterium tuberculosis enoyl reductase as a prototype of a new class of chemotherapeutic agents to treat tuberculosis. *Journal of the Brazilian Chemical Society*, **2010**, 21, 1384-1389	1.5	21
99	On the selective detection of duplex deoxyribonucleic acids by 2,1,3-benzothiadiazole fluorophores. *Molecular BioSystems*, **2010**, 6, 967-75		23

98	Crystal structure and molecular dynamics studies of human purine nucleoside phosphorylase complexed with 7-deazaguanine. *Journal of Structural Biology*, **2010**, 169, 379-88	3.4	5
97	Structural and functional analyses of Mycobacterium tuberculosis Rv3315c-encoded metal-dependent homotetrameric cytidine deaminase. *Journal of Structural Biology*, **2010**, 169, 413-23	3.4	14
96	The kinetic mechanism of human uridine phosphorylase 1: Towards the development of enzyme inhibitors for cancer chemotherapy. *Archives of Biochemistry and Biophysics*, **2010**, 497, 35-42	4.1	16
95	Crystallographic and docking studies of purine nucleoside phosphorylase from Mycobacterium tuberculosis. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 4769-74	3.4	24
94	Comparison between Two Erwinia carotovora L-Asparaginase II Constructions: cloning, Heterologous Expression, Purification, and Kinetic Characterization. *Journal of Microbial & Biochemical Technology*, **2010**, 02, 013-019		8
93	Human Interferon ˆ ?ˆ ?1ser17: Coding DNA Synthesis, Expression, Purification and Characterization of Bioactive Recombinant Protein. *Journal of Microbial & Biochemical Technology*, **2010**, 02,		2
92	The Rv1712 Locus from Mycobacterium tuberculosis H37Rv codes for a functional CMP kinase that preferentially phosphorylates dCMP. *Journal of Bacteriology*, **2009**, 191, 2884-7	3.5	12
91	The conserved Lysine69 residue plays a catalytic role in Mycobacterium tuberculosis shikimate dehydrogenase. *BMC Research Notes*, **2009**, 2, 227	2.3	7
90	Molecular modeling and dynamics studies of purine nucleoside phosphorylase from Bacteroides fragilis. *Journal of Molecular Modeling*, **2009**, 15, 913-22	2	4
89	Molecular modeling, dynamics and docking studies of purine nucleoside phosphorylase from Streptococcus pyogenes. *Biophysical Chemistry*, **2009**, 142, 7-16	3.5	9
88	Hypoxanthine-guanine phosphoribosyltransferase from Mycobacterium tuberculosis H37Rv: cloning, expression, and biochemical characterization. *Protein Expression and Purification*, **2009**, 66, 185-90	2	16
87	Molecular cloning, expression in Escherichia coli and production of bioactive homogeneous recombinant human granulocyte and macrophage colony stimulating factor. *International Journal of Biological Macromolecules*, **2009**, 45, 97-102	7.9	29
86	Homogeneous recombinant Mycobacterium tuberculosis shikimate dehydrogenase production: an essential step towards target-based drug design. *International Journal of Biological Macromolecules* , **2009**, 45, 200-5	7.9	2
85	Steady-state kinetics of indole-3-glycerol phosphate synthase from Mycobacterium tuberculosis. *Archives of Biochemistry and Biophysics*, **2009**, 486, 19-26	4.1	17
84	Substrate specificity and kinetic mechanism of purine nucleoside phosphorylase from Mycobacterium tuberculosis. *Archives of Biochemistry and Biophysics*, **2009**, 486, 155-64	4.1	22
83	Structural studies of PNP from Toxoplasma gondii. *International Journal of Bioinformatics Research and Applications*, **2009**, 5, 154-62	0.9	
82	Identification of Rv3852 as a nucleoid-associated protein in Mycobacterium tuberculosis. *Microbiology (United Kingdom)*, **2009**, 155, 2652-2663	2.9	14
81	Mycobacterium tuberculosis beta-ketoacyl-ACP reductase: alpha-secondary kinetic isotope effects and kinetic and equilibrium mechanisms of substrate binding. *Archives of Biochemistry and Biophysics*, **2008**, 471, 1-10	4.1	13

80	Structural studies of human purine nucleoside phosphorylase: towards a new specific empirical scoring function. *Archives of Biochemistry and Biophysics*, **2008**, 479, 28-38	4.1	30
79	Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization. *Microbial Cell Factories*, **2008**, 7, 13	6.4	44
78	Dynamics of glyphosate-induced conformational changes of Mycobacterium tuberculosis 5-enolpyruvylshikimate-3-phosphate synthase (EC 2.5.1.19) determined by hydrogen-deuterium exchange and electrospray mass spectrometry. *Biochemistry*, **2008**, 47, 7509-22	3.2	27
77	Virtual Screening of Drugs: Score Functions, Docking, and Drug Design. *Current Computer-Aided Drug Design*, **2008**, 4, 265-272	1.4	27
76	The two chorismate mutases from both Mycobacterium tuberculosis and Mycobacterium smegmatis: biochemical analysis and limited regulation of promoter activity by aromatic amino acids. *Journal of Bacteriology*, **2008**, 190, 122-34	3.5	18
75	The Mode of Inhibition of Mycobacterium tuberculosis Wild-Type and Isoniazid-Resistant 2-Trans-Enoyl-ACP(CoA) Reductase Enzymes by An Inorganic Complex. *Anti-Infective Agents in Medicinal Chemistry*, **2008**, 7, 50-62		14
74	Structural bioinformatics study of PNP from Listeria monocytogenes. *Protein and Peptide Letters*, **2008**, 15, 843-9	1.9	5
73	Molecular modeling and dynamics studies of cytidylate kinase from Mycobacterium tuberculosis H37Rv. *Journal of Molecular Modeling*, **2008**, 14, 427-34	2	15
72	The Mycobacterium tuberculosis Rv2540c DNA sequence encodes a bifunctional chorismate synthase. *BMC Biochemistry*, **2008**, 9, 13	4.8	14
71	Structural studies of shikimate 5-dehydrogenase from Mycobacterium tuberculosis. *Proteins: Structure, Function and Bioinformatics*, **2008**, 72, 720-30	4.2	18
70	Structural studies of prephenate dehydratase from Mycobacterium tuberculosis H37Rv by SAXS, ultracentrifugation, and computational analysis. *Proteins: Structure, Function and Bioinformatics*, **2008**, 72, 1352-62	4.2	6
69	Molecular modeling and dynamics simulations of PNP from Streptococcus agalactiae. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 4984-93	3.4	32
68	The catalytic mechanism of indole-3-glycerol phosphate synthase (IGPS) investigated by electrospray ionization (tandem) mass spectrometry. *Tetrahedron Letters*, **2008**, 49, 5914-5917	2	6
67	New sensitive fluorophores for selective DNA detection. *Organic Letters*, **2007**, 9, 4001-4	6.2	59
66	A structural model for chorismate synthase from Mycobacterium tuberculosis in complex with coenzyme and substrate. *Computers in Biology and Medicine*, **2007**, 37, 149-58	7	8
65	Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase from Mycobacterium tuberculosis. *Acta Crystallographica Section F: Structural Biology Communications*, **2007**, 63, 1-6		27
64	Chorismate synthase: an attractive target for drug development against orphan diseases. *Current Drug Targets*, **2007**, 8, 437-44	3	44
63	Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents. *Current Drug Targets*, **2007**, 8, 399-411	3	21

62	Mycobacterial shikimate pathway enzymes as targets for drug design. *Current Drug Targets*, **2007**, 8, 423-35	3	62
61	Functional characterization by genetic complementation of aroB-encoded dehydroquinate synthase from Mycobacterium tuberculosis H37Rv and its heterologous expression and purification. *Journal of Bacteriology*, **2007**, 189, 6246-52	3.5	18
60	Purine nucleoside phosphorylase: a potential target for the development of drugs to treat T-cell- and apicomplexan parasite-mediated diseases. *Current Drug Targets*, **2007**, 8, 413-22	3	15
59	The inhibition of 5-enolpyruvylshikimate-3-phosphate synthase as a model for development of novel antimicrobials. *Current Drug Targets*, **2007**, 8, 445-57	3	44
58	Shikimate kinase: a potential target for development of novel antitubercular agents. *Current Drug Targets*, **2007**, 8, 459-68	3	38
57	Kinetic and chemical mechanisms of shikimate dehydrogenase from Mycobacterium tuberculosis. *Archives of Biochemistry and Biophysics*, **2007**, 457, 123-33	4.1	12
56	Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. *Journal of Structural Biology*, **2007**, 159, 369-80	3.4	44
55	Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. *Current Pharmaceutical Design*, **2006**, 12, 2409-24	3.3	30
54	Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein (ACP) reductase: kinetic and chemical mechanisms. *Biochemistry*, **2006**, 45, 13064-73	3.2	20
53	Phosphate closes the solution structure of the 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) from Mycobacterium tuberculosis. *Archives of Biochemistry and Biophysics*, **2006**, 452, 156-64	4.1	19
52	Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis. *Journal of Molecular Biology*, **2006**, 359, 646-66	6.5	55
51	Structure of chorismate synthase from Mycobacterium tuberculosis. *Journal of Structural Biology*, **2006**, 154, 130-43	3.4	36
50	Functional shikimate dehydrogenase from Mycobacterium tuberculosis H37Rv: purification and characterization. *Protein Expression and Purification*, **2006**, 46, 429-37	2	20
49	The resumption of consumption -- a review on tuberculosis. *Memorias Do Instituto Oswaldo Cruz*, **2006**, 101, 697-714	2.6	100
48	Crystallization and preliminary X-ray diffraction analysis of prephenate dehydratase from Mycobacterium tuberculosis H37Rv. *Acta Crystallographica Section F: Structural Biology Communications*, **2006**, 62, 357-60		3
47	Molecular models of tryptophan synthase from mycobacterium tuberculosis complexed with inhibitors. *Cell Biochemistry and Biophysics*, **2006**, 44, 375-84	3.2	12
46	Determining the structural basis for specificity of ligands using crystallographic screening. *Cell Biochemistry and Biophysics*, **2006**, 44, 405-11	3.2	6
45	Crystal structure of human PNP complexed with hypoxanthine and sulfate ion. *Biochemical and Biophysical Research Communications*, **2005**, 326, 335-8	3.4	30

44	New catalytic mechanism for human purine nucleoside phosphorylase. *Biochemical and Biophysical Research Communications*, **2005**, 327, 646-9	3.4	41
43	DAHP synthase from Mycobacterium tuberculosis H37Rv: cloning, expression, and purification of functional enzyme. *Protein Expression and Purification*, **2005**, 40, 23-30	2	18
42	Kinetics and crystal structure of human purine nucleoside phosphorylase in complex with 7-methyl-6-thio-guanosine. *Archives of Biochemistry and Biophysics*, **2005**, 442, 49-58	4.1	34
41	Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities. *Biophysical Journal*, **2005**, 89, 876-84	2.9	45
40	The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases--a review. *Memorias Do Instituto Oswaldo Cruz*, **2005**, 100, 475-506	2.6	58
39	Electron transfer kinetics and mechanistic study of the thionicotinamide coordinated to the pentacyanoferrate(III)/(II) complexes: a model system for the in vitro activation of thioamides anti-tuberculosis drugs. *Journal of Inorganic Biochemistry*, **2005**, 99, 368-75	4.2	18
38	Molecular models of protein targets from Mycobacterium tuberculosis. *Journal of Molecular Modeling*, **2005**, 11, 160-6	2	20
37	Structure of human PNP complexed with ligands. *Acta Crystallographica Section D: Biological Crystallography*, **2005**, 61, 856-62		24
36	Structure Prediction and Docking Studies of Chorismate Synthase from Mycobacterium Tuberculosis. *Lecture Notes in Computer Science*, **2005**, 118-127	0.9	1
35	Purine nucleoside phosphorylase activity in rat cerebrospinal fluid. *Neurochemical Research*, **2004**, 29, 1831-5	4.6	11
34	Crystallization and preliminary X-ray crystallographic analysis of chorismate synthase from Mycobacterium tuberculosis. *Acta Crystallographica Section D: Biological Crystallography*, **2004**, 60, 2003-5		8
33	Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid. *Acta Crystallographica Section D: Biological Crystallography*, **2004**, 60, 2310-9		33
32	An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. *Chemical Communications*, **2004**, 312-3	5.8	51
31	Structures of human purine nucleoside phosphorylase complexed with inosine and ddI. *Biochemical and Biophysical Research Communications*, **2004**, 313, 907-14	3.4	47
30	Molecular models for shikimate pathway enzymes of Xylella fastidiosa. *Biochemical and Biophysical Research Communications*, **2004**, 320, 979-91	3.4	25
29	Structural bioinformatics study of PNP from Schistosoma mansoni. *Biochemical and Biophysical Research Communications*, **2004**, 322, 100-4	3.4	28
28	Crystallographic structure of PNP from Mycobacterium tuberculosis at 1.9A resolution. *Biochemical and Biophysical Research Communications*, **2004**, 324, 789-94	3.4	23
27	Interaction of shikimic acid with shikimate kinase. *Biochemical and Biophysical Research Communications*, **2004**, 325, 10-7	3.4	5

26	Selection of an Escherichia coli host that expresses mutant forms of Mycobacterium tuberculosis 2-trans enoyl-ACP(CoA) reductase and 3-ketoacyl-ACP(CoA) reductase enzymes. *Protein Expression and Purification*, **2004**, 34, 118-25	2	7
25	Docking and small angle X-ray scattering studies of purine nucleoside phosphorylase. *Biochemical and Biophysical Research Communications*, **2003**, 309, 923-928	3.4	37
24	Structural basis for inhibition of human PNP by immucillin-H. *Biochemical and Biophysical Research Communications*, **2003**, 309, 917-22	3.4	41
23	Structural bioinformatics study of EPSP synthase from Mycobacterium tuberculosis. *Biochemical and Biophysical Research Communications*, **2003**, 312, 608-14	3.4	43
22	Crystal structure of human PNP complexed with guanine. *Biochemical and Biophysical Research Communications*, **2003**, 312, 767-72	3.4	37
21	Crystal structure of human purine nucleoside phosphorylase at 2.3A resolution. *Biochemical and Biophysical Research Communications*, **2003**, 308, 545-52	3.4	52
20	Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. *Biochemical and Biophysical Research Communications*, **2003**, 308, 553-9	3.4	52
19	Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase. *Protein Expression and Purification*, **2003**, 27, 158-64	2	34
18	One-step purification of 5-enolpyruvylshikimate-3-phosphate synthase enzyme from Mycobacterium tuberculosis. *Protein Expression and Purification*, **2003**, 28, 287-92	2	16
17	Ionic states of substrates and transition state analogues at the catalytic sites of N-ribosyltransferases. *Biochemistry*, **2003**, 42, 5694-705	3.2	39
16	Over-the-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase. *Biochemistry*, **2003**, 42, 6057-66	3.2	54
15	Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. *Current Pharmaceutical Biotechnology*, **2002**, 3, 197-225	2.6	109
14	Molecular model of shikimate kinase from Mycobacterium tuberculosis. *Biochemical and Biophysical Research Communications*, **2002**, 295, 142-8	3.4	46
13	Cloning and expression of functional shikimate dehydrogenase (EC 1.1.1.25) from Mycobacterium tuberculosis H37Rv. *Protein Expression and Purification*, **2002**, 26, 59-64	2	27
12	Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. *Protein Expression and Purification*, **2001**, 22, 430-5	2	48
11	Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition by a transition-state analogue and dissection by parts. *Biochemistry*, **2001**, 40, 8196-203	3.2	55
10	Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces. *Biochemistry*, **2001**, 40, 8204-15	3.2	52
9	Cooperativity between trimers of the hexameric glutamate dehydrogenase from Clostridium symbiosum. *BBA - Proteins and Proteomics*, **1998**, 1382, 345-50		

8	Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. *Journal of Infectious Diseases*, **1998**, 178, 769-75	7	109
7	Resistance to antitubercular drugs. *Advances in Experimental Medicine and Biology*, **1998**, 456, 115-44	3.6	48
6	Kinetic studies on the binding of 1,N6-etheno-NAD+ to glutamate dehydrogenase from Clostridium symbiosum. *BBA - Proteins and Proteomics*, **1997**, 1340, 63-71		6
5	Kinetics of Inactivation of WT and C243S Mutant of Mycobacterium tuberculosis Enoyl Reductase by Activated Isoniazid. *Journal of the American Chemical Society*, **1996**, 118, 11301-11302	16.4	38
4	The mechanism of substrate and coenzyme binding to clostridial glutamate dehydrogenase during reductive amination. *FEBS Journal*, **1995**, 234, 603-15		12
3	Initial formation of a non-covalent enzyme-reagent complex during the inactivation of clostridial glutamate dehydrogenase by Ellman's reagent: determination of the enzyme's dissociation constant for the binary complex with NAD+ from protection studies. *BBA - Proteins and Proteomics*,		12
2	Steady-state kinetics and transient studies of substrate and coenzyme analogue binding to clostridial glutamate dehydrogenase (GDH) during oxidative deamination. *Biochemical Society Transactions*, **1994**, 22, 319S	5.1	1
1	The mechanism of substrate and coenzyme binding to clostridial glutamate dehydrogenase during oxidative deamination. *FEBS Journal*, **1993**, 213, 935-45		13